

4 August 2025

## Osteopore wins 2 public hospital tender bids in Vietnam for its orthopaedic products

### Highlights

- On 27 March 2024, Osteopore secured Singapore and Vietnam market approvals for its orthopaedic products<sup>1</sup>.
- Osteopore has won tender bids thereby gaining entry into two major public hospitals in Vietnam.
- Products included in the successful tender bids include Osteopore's centerpiece product for high tibial osteotomy (HTO), and other products for bone grafting applications.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX:OSX; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that it has gained entry into two major public hospitals in Vietnam for its orthopaedic products.

The products that are successful in the tender bids included Osteopore's centerpiece product for high tibial osteotomy (HTO), and other products for bone grafting applications.

The tender value for both hospitals is approximately AUD 90,000 over the first 12 months.

The high growth HTO market is projected to grow at a CAGR of 9.2% with procedures expected to reach 35,000 in the Asia Pacific region (APAC) annually by 2025<sup>2</sup>.

---

<sup>1</sup> ASX announcement "Osteopore secures Singapore and Vietnam market approvals", 27 March 2024.

<sup>2</sup> Commissioned research (data on file), 2020.



Moreover, it is anticipated that the bone grafting market will increase at a CAGR of 2.3%, with procedures are expected to reach 250,000 in APAC annually by 2025<sup>2</sup>.

Vietnam's orthopaedic market is forecasted to experience robust growth at a 7.68% CAGR between 2024 and 2028<sup>3</sup>. This projected expansion is driven by the country's significantly aging population and the increasing prevalence of orthopaedic conditions, which will heighten demand for related products and services.

The next step for the Company is to work with its distribution partner in Vietnam to finalise logistics and supply arrangements with the two hospitals, which is expected to complete over the next 3 months.

**Commenting on gaining entry into two major public hospitals for its orthopaedic products in Vietnam, Osteopore CEO Dr Lim Yujing, said:**

"We are delighted that our regenerative orthopaedic products have been recognised and selected by the Vietnamese surgeons and hospitals.

"With these successful tenders, our experience operating in Vietnam through our experienced distribution partner and the confidence in our clinical outcomes, we are executing key steps to capture an important growing market.

"We are working towards making further commercial progress for our orthopaedic products not just in Vietnam, but also in other markets that we have identified", said Dr Lim.

**ENDS**

*This announcement has been authorised for release by the Board of Osteopore Limited.*

For more information, please contact:

**Dr. Yujing Lim**  
CEO & CTO  
Osteopore Limited  
E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**  
Executive Chairman  
Osteopore Limited  
E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across

---

<sup>3</sup> <https://www.statista.com/outlook/hmo/medical-technology/medical-devices/orthopedic-devices/vietnam>



multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

